RxDoctor Payments Data

Holly Shalhoop, PA

Physician Assistant · Cumming, GANPI 1578867040

Payments from drug & device makers

$4,965in general payments, 2019–2025

Across 191 payments — averaging $25.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$442
  • Pfizer$440
  • Bayer$404
  • Axonics, Inc.$298
  • Astellas Pharma US Inc$268
  • Teleflex LLC$256
  • plus $3K from 34 others

What the payments were for

  • Travel & lodging$110%
  • Food & beverage$4,74396%
  • Education$2114%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,965 in reported general payments places this provider in the 90th percentile of 3,581 physician assistant providers in Georgia.

See all physician assistant providers in Georgia

Medicare billing

Part B allowed, 2024
$229,857
Medicare patients
474
Services billed
11,104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide15$211,035
MyrbetriqMirabegron126$87,060
GemtesaVibegron71$56,718
Tamsulosin Hcl261$3,224
Trospium Chloride ErTrospium Chloride17$2,505
Solifenacin Succinate44$1,662
Oxybutynin Chloride ErOxybutynin Chloride82$1,653
Estradiol24$1,389
Methenamine Hippurate22$1,377
Darifenacin ErDarifenacin Hydrobromide12$1,239
Potassium Citrate ErPotassium Citrate14$907
Finasteride50$623
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst47$528
Testosterone Cypionate12$473
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav56$426

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$156$211,03515 claims
Astellas Pharma US IncMyrbetriq$268$87,060126 claims
Sumitomo Pharma America, Inc.Gemtesa$212$56,71871 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,581 physician assistant providers in Georgia.

Other physician assistant in Cumming

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →